Concomitant BTK inhibition may subvert the upregulation of alternative BCL2 family proteins by the tumor microenvironment, and combination trials have demonstrated frequent deep remission in CLL and MCL [29, 78, 149, 150]. The gene discussed is BCL2; the disease is mantle cell lymphoma.